Avelumab shows survival benefit against advanced urothelial cancer

Reuters Health - 21/09/2020 - Adding avelumab to the best supportive care as maintenance therapy for advanced or metastatic urothelial cancer can significantly extend overall survival by 31% and progression-free survival by 38%, according to the results of the JAVELIN Bladder 100 study. Overall median survival was 21.4 months with the drug versus 14.3 months with best supportive care. That translated to one-year survival rates of 71.3% with avelumab and 58.4% without (P=0.001). But the volunteers didn't go long without the tumor getting worse. Median progression-free survival lasted only 3.7 months with the drug versus 2.0 months in the control group. "Separation of the overall survival curves and the progression-free survival curves in favor of avelumab occurred early in the course of treatment and was maintained," said the team, led by Dr. Thomas Powles of Queen Mary University of London. The avelumab group had nearly double the rate of advers...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 21 September, 202029 September, 2020